Healthcare Platform Clears Major Security Milestone After Independent Audit

1. Rocket Doctor is a billboard sponsor of Streetwise Reports and pays SWR a monthly sponsorship fee between US$3,000 and US$6,000. 
2. As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Rocket Doctor.
3. James Guttman wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. 
4.  This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
5. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1 Disclosure for the quote from the Stewart Thomson article published on March 17, 2026

1. For the quoted article (published on March 17, Rocket Doctor has paid Street Smart, an affiliate of Streetwise Reports, US$2,500
2. Author Certification and Compensation: Stewart Thomson was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Thomson is a retired Canadian financial advisor who has passed the Canadian Securities Course as well as additional technical analysis courses that were mandated by his former employer and approved by Ontario regulatory bodies. For the past 15 years, he has been editing and writing numerous financial newsletters that have a strong focus on charts.  The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.

2. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) announced that its wholly owned digital health platform and marketplace, Rocket Doctor Inc., has achieved SOC 2 Type I compliance following an independent third-party audit that evaluated its security, privacy, and operational controls.

Rocket Doctor AI said the certification further underscores the company's commitment to maintaining security, privacy, and operational standards while protecting sensitive patient and partner information. According to the company, SOC 2 Type I is a framework developed by the American Institute of Certified Public Accountants (AICPA) to evaluate how organizations protect sensitive customer data.

The company said the independent audit assessed Rocket Doctor's controls over an extended period and verified that its security, availability, confidentiality, and privacy practices are designed and operating effectively. Rocket Doctor AI stated that the examination reviewed its information security and access management practices, data privacy and confidentiality controls, incident response and business continuity planning, risk management and governance processes, and secure system development and change management procedures. According to the company, the audit demonstrated that these controls are properly designed and implemented across the organization.

Rocket Doctor AI said it has invested in governance, cybersecurity infrastructure, risk management, and compliance programs since the platform's inception and dedicated substantial resources over the past eight months toward achieving SOC 2 Type I compliance as part of its broader enterprise growth strategy.

"As healthcare increasingly relies on digital infrastructure, data security and compliance have become baseline requirements for technology adoption," said Harry Cherniak, cofounder, Chief Privacy Officer, and COO of Rocket Doctor Inc., in a company news release. "Achieving SOC 2 Type I compliance validates the rigorous controls and processes we've built to safeguard patient and partner data. This milestone provides healthcare organizations, employers, payors, pharmacies, and government partners with independent assurance that Rocket Doctor meets the highest standards for security and operational integrity."

The company said the certification provides healthcare organizations, employers, payors, pharmacies, and government partners with independent assurance that its systems and processes meet industry-recognized security standards. Rocket Doctor AI added that achieving SOC 2 Type I compliance strengthens its ability to support enterprise healthcare partners by providing a validated security framework that streamlines procurement and onboarding processes for large-scale health systems, employers, insurers, and pharmacy networks.

Digital Health Sector Continued to Expand as AI Investment Accelerated

According to a July 12 report from Grand View Research, the global digital health market was valued at US$347.4 billion in 2025 and was estimated to reach US$420.2 billion in 2026. The firm projected the market would grow to US$1.83 trillion by 2033 at a compound annual growth rate of 23.4%. Grand View Research stated that "the market is driven by several factors, such as a strong domestic digital health market for telehealth platform developers, mHealth app providers, wearable device manufacturers, and e-prescription systems."

The report identified North America as the largest regional market, accounting for 37.1% of global revenue in 2025. It also found that software represented the largest component segment with a 45.7% revenue share, while telehealthcare accounted for the largest technology segment at 44.7%. Grand View Research stated that "digital health tools can help patients track their health, adhere to treatment plans, and communicate more effectively with healthcare providers," while noting that telehealth platforms and secure messaging applications facilitated consultations and treatment adjustments without requiring in-person visits.

Also on July 12, Tracxn reported that the global HealthTech sector included approximately 145,000 companies, with 26,800 funded companies that had collectively raised US$384 billion in venture capital and private equity. The research firm stated, "This sector includes companies providing digital health solutions for disease management, diagnosis, treatment, etc." It also noted that the sector encompassed "both B2B and B2C software, platforms, and connected devices for providers, hospitals, consumers, employers, and the life science industry."

Tracxn reported that the HealthTech sector had produced 964 initial public offerings and approximately 5,230 acquisitions, while total funding reached US$14.5 billion during 2026 to date. It also stated that HealthTech was "also known as Digital Health, e-Health, Health And Wellness Tech, Smart Healthcare, Healthcare Technology or Health Management Technology."

According to a July 13 report by Heather Landi in Fierce Healthcare, digital health companies raised US$7.4 billion across 244 venture capital deals during the first half of 2026, compared with US$6.4 billion during the same period a year earlier. Citing Rock Health researchers Ashwini Nagappan, Jason Lei, and Maddie Knowles, the report stated that investment continued to concentrate in larger financings, with 20 megadeals of US$100 million or more accounting for 45% of capital invested.

Rock Health researchers wrote, "As AI changes what's easy to build, competitive advantage increasingly comes from qualities that are difficult to replicate." They also stated, "As foundation models improve and AI capabilities become easier to build, technical differentiation is becoming harder to sustain. Investors and buyers are not asking, 'Who has AI?' but instead, 'Who has something AI alone can't provide?'"

Technical Analyst Saw AI Healthcare Platform Building Momentum With Strong Speculative Buy Rating

¹In a March 17 report, technical analyst Stewart Thomson discussed Rocket Doctor AI Inc. and described the company as "committed to empowering both physicians and patients with access to personalized healthcare regardless of who they are, where they are, or what their lifestyle brings." He wrote that the company's AI platform "is designed by doctors, so doctors who use it get exactly what they need" and that its digital health platform and marketplace "helps to make healthcare more accessible and efficient, especially for those in rural communities."

Thomson stated that Rocket Doctor's technology "is dedicated to transforming healthcare by empowering patients, providers, and healthcare systems through advances in technology," adding that "the approach is centered on enhancing provider capabilities, not replacing clinical decisions." He also wrote that virtual appointments "are designed to provide high-quality care that is comparable to in-person visits" and that the platform "connects patients with board-certified healthcare providers who can diagnose, treat, and manage a wide range of health concerns," while supporting "20 other specialties."

The report highlighted several operational features, including a clinician-built platform, smart triage system, smart matching technology, enhanced care delivery tools, multilingual care through a partnership with Voyce, and remote patient monitoring. Thomson also noted that Rocket Doctor had expanded its New York footprint through in-network agreements, including one that "extends Rocket Doctor's total in-network reach to over 15 million members nationwide," and referenced a US$1 million Healthy Aging Program grant launched in partnership with CVS Health Foundation to connect more than 700 patients to primary, urgent, and mental health care by the second quarter of 2026.

Discussing the company's U.S. positioning, Thomson wrote, "Building a successful digital health practice in the U.S. is hard; competitors face a minimum of 18 to 24+ months to replicate the position Rocket Doctor AI is in today, technology, payer contracts, credentialing, and revenue ops...with no guarantee of success." He also stated that "lead volume for scaling physicians utilizing the platform is bringing in eight qualified leads/month across MA, Commercial, Medicaid, and 50% MoM growth as plans go live."

From a technical perspective, Thomson assigned Rocket Doctor AI a Strong Speculative Buy technical rating and identified a short-term technical price target of CA$0.80, a medium-term technical price target of CA$1.00, and a long-term technical price target of CA$1.60.

Enterprise Healthcare Expansion and AI Platform Development

Rocket Doctor AI said it is continuing to expand its healthcare services across North America through its physician-built, AI-powered healthcare platform. The company stated that its proprietary Global Library of Medicine (GLM) is a clinically validated decision support system developed with input from hundreds of physicians worldwide, while Rocket Doctor Inc. operates an AI-powered digital health platform and marketplace.

According to the company's July 2026 investor presentation, Rocket Doctor's platform has supported more than 750,000 patient visits through a network of more than 350 physicians across Alberta, British Columbia and Ontario, while expanding operations in California, Maryland and New York through payer partnerships.

The investor presentation also states that the company is pursuing additional U.S. state expansion, including Florida and Texas, while extending existing relationships with payers. It reports in-network patient access of 9,875,993 in New York, 8,126,637 in California, and 3,180,599 in Maryland.

Rocket Doctor AI's investor presentation further states that the company has 16 clinically active U.S. physicians, 46 physicians in the credentialing process, and MD capacity pending, which it describes as three times current levels.

Ownership and Share Structure²

Insider ownership of Rocket Doctor AI totals 4.29%. Retail investors hold the rest.

Rocket Doctor AI has 99.16 million shares outstanding. Its market cap is CA$59.50M. Its 52-week range is CA$0.33–0.98/share.